N-Acetyl Epithalon Amidate [Nasal Spray]

Description

What is N-Acetyl Epithalon Amidate Nasal Spray?

N-Acetyl Epithalon Amidate (Ac-AEDG-NH2) is a doubly end-capped synthetic derivative of Epithalon (Epitalon; Ala-Glu-Asp-Gly; AEDG), a tetrapeptide originally synthesized at the St. Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson and colleagues in the 1990s. Epithalon was derived from the amino acid composition of Epithalamin, a bovine pineal gland polypeptide extract, and was subsequently found to occur in the pineal gland polypeptide complex. The N-Acetyl Epithalon Amidate form adds N-terminal acetylation (Ac-) and C-terminal amidation (-NH2) to the core AEDG tetrapeptide sequence. These two end-capping modifications reduce susceptibility to exopeptidase-mediated degradation, alter the peptide’s charge distribution, and improve conformational consistency relative to the unmodified free acid form. N-Acetyl Epithalon Amidate has not been approved as a registered pharmaceutical in any country and has not been approved by the Food and Drug Administration for any indication.

The parent compound Epithalon has been extensively investigated across preclinical and in vitro model systems over the past 25 years for its geroprotective, neuroendocrine, antioxidant, and antimutagenic properties. Research has characterized effects including telomerase activity modulation, melatonin synthesis regulation, neurogenic differentiation gene expression, interleukin-2 mRNA level changes, and chromatin-level interactions relevant to gene transcription initiation [Araj et al., 2025; PMID 40141333]. The nasal spray formulation is studied as a preclinical research delivery route. Intranasal delivery bypasses hepatic first-pass metabolism relative to systemic routes and provides access to olfactory bulb-mediated CNS transport pathways in preclinical rodent model preparations.

DISCLAIMER: N-Acetyl Epithalon Amidate Nasal Spray as supplied by RCDbio, is not a dietary supplement and has not been approved by the Food and Drug Administration for human use, veterinary use, consumption, or any therapeutic application. This product is not intended for human consumption or therapeutic self-administration. It is supplied exclusively for in vitro and preclinical laboratory research purposes. All RCDbio research compounds are for laboratory and research purposes only.

Chemical Properties of N-Acetyl Epithalon Amidate

How Does N-Acetyl Epithalon Amidate Work?

N-Acetyl Epithalon Amidate delivers the biological activity of the AEDG tetrapeptide core sequence with improved metabolic stability conferred by N-terminal acetylation and C-terminal amidation. The parent compound Epithalon has been characterized as a peptide bioregulator with multiple proposed mechanisms of action, including direct DNA interaction in the major groove of the double helix, telomerase promoter binding, histone interaction relevant to chromatin remodeling, and neuroendocrine modulation of the pineal gland and melatonin synthesis pathway. No single confirmed receptor target has been established. The following mechanistic observations are from preclinical and in vitro data only.

Terminal Modification and Metabolic Stability

N-terminal acetylation (Ac-) removes the free amino group from the peptide’s N-terminus, preventing aminopeptidase-mediated cleavage at the N-terminal Ala residue. C-terminal amidation (-NH2) removes the free carboxyl group from the C-terminal Gly residue, preventing carboxypeptidase-mediated degradation at the C-terminus. Together, these end-capping modifications confer resistance to exopeptidase activity in biological fluids, including plasma and nasal mucosal secretions, extending the effective exposure time relative to the unmodified Epitalon free acid in research preparations. The core AEDG sequence and its proposed biological interactions are retained.

DNA Major Groove Binding and Telomerase Promoter Interaction

Using a complementary binding model, the AEDG tetrapeptide was shown to preferentially bind to the base pair sequence ATTTTC in the major groove of the DNA double helix. This sequence and its reverse complement were found repeatedly in the promoter region of the telomerase gene, suggesting that Epitalon may interact directly with telomerase gene regulatory elements. Statistical information analysis confirmed that regulatory peptides and oligonucleotide sequences share information content characteristics consistent with a molecular recognition mechanism for gene transcription initiation [Khavinson et al., 2005; PMID 15990728].

Epigenetic Gene Regulation via Histone Interaction

In human gingival mesenchymal stem cell (hGMSC) preparations, the AEDG peptide increased the synthesis of neurogenic differentiation markers, including Nestin, GAP43, beta-Tubulin III, and Doublecortin. mRNA expression of these neurogenic differentiation genes was increased by 1.6-1.8 times relative to controls. Molecular modeling showed that the AEDG peptide preferentially binds to H1/6 and H1/3 histones at sites that interact with DNA, suggesting a chromatin-level epigenetic mechanism for gene expression regulation [Khavinson et al., 2020; PMID 32019204].

Geroprotective, Neuroendocrine, and Antioxidant Effects

A comprehensive review of Epithalon research published in 2025 confirmed significant geroprotective and neuroendocrine effects across in vitro, in vivo, and in silico studies over 25 years. Documented biological activities include direct effects on melatonin synthesis, changes in interleukin-2 mRNA levels, modulation of murine thymocyte mitogenic activity, enhancement of telomerase activity, acetylcholinesterase and butyrylcholinesterase activity enhancement, and antioxidant and antimutagenic effects in animal model preparations. The mechanisms underlying these observations remain incompletely characterized [Araj et al., 2025; PMID 40141333].

Intranasal Delivery & Pharmacokinetics

Olfactory Bulb-Mediated CNS Transport

When administered intranasally in preclinical rodent model systems, peptide compounds can access the central nervous system through the olfactory nerve (cranial nerve I) pathway. Compounds deposited on the olfactory mucosa are transported along olfactory axons through the cribriform plate to the olfactory bulb, from which access to deeper CNS structures has been characterized in rodent preparations. The olfactory and trigeminal nerve pathways for nose-to-brain peptide transport have been investigated in preclinical studies of peptide and protein delivery [Wong et al., 2024; PMID 38441832]. No compound-specific olfactory transport data for N-Acetyl Epithalon Amidate has been published. The compound’s neuroendocrine and pineal gland-related research context makes intranasal delivery a pharmacologically relevant route for CNS-directed research applications.

Hepatic First-Pass Metabolism Bypass

The intranasal route avoids portal circulation and hepatic first-pass metabolic processing. The AEDG tetrapeptide core is a small, hydrophilic peptide susceptible to peptidase activity in the GI environment. The N-terminal acetylation and C-terminal amidation confer partial resistance to exopeptidase activity at the nasal mucosa. These observations are derived from structural chemistry principles and preclinical peptide stability data and do not constitute evidence of efficacy via any route in human subjects.

Nasal Mucosal Absorption

N-Acetyl Epithalon Amidate has an approximate molar mass of 431.43 g/mol (~0.43 kDa). This molecular weight falls well below the 1 kDa threshold, indicating that transcellular lipid-bilayer diffusion and paracellular transport are both plausible absorption mechanisms at the nasal mucosa. At this size, nasal mucosal absorption is expected to be significantly less restricted by molecular weight relative to larger research peptides in the RCDbio nasal spray range. Specific nasal mucosal permeability coefficients for N-Acetyl Epithalon Amidate have not been published.

Compound-Specific Pharmacokinetics

No formal pharmacokinetic data for N-Acetyl Epithalon Amidate via any route has been published in the peer-reviewed literature as of June 2026. Published Epitalon data relates primarily to biological activity endpoints rather than formal pharmacokinetic parameters. The end-capping modifications are expected to extend exposure relative to the unmodified peptide based on reduced exopeptidase susceptibility. Researchers should account for the absence of published pharmacokinetic parameters when designing laboratory protocols.

Key Research Findings

DNA Major Groove Binding and Telomerase Promoter Recognition (In Silico / Biopolymer Chemistry Model): Complementary binding modeling identified the base pair sequence ATTTTC as a specific binding site for the AEDG peptide in the major groove of the DNA double helix; this sequence and its reverse complement were found repeatedly in the telomerase gene promoter region; statistical analysis confirmed mutual information content between regulatory peptides and oligonucleotide sequences consistent with gene transcription initiation recognition [Khavinson et al., 2005; PMID 15990728]

Epigenetic Neurogenic Gene Expression Regulation (Human Gingival Mesenchymal Stem Cell Preparation): AEDG peptide increased expression of neurogenic differentiation markers Nestin, GAP43, beta-Tubulin III, and Doublecortin by 1.6-1.8 fold at the mRNA and protein level in hGMSC preparations; molecular modeling confirmed preferential AEDG binding to H1/6 and H1/3 histones at DNA-interacting sites, suggesting histone-mediated epigenetic regulation of neurogenic gene transcription [Khavinson et al., 2020; PMID 32019204]

Comprehensive Review — Geroprotective, Telomerase, and Neuroendocrine Effects (Review of 25 Years of Epitalon Research): Systematic review confirmed significant geroprotective and neuroendocrine effects of Epitalon across in vitro, in vivo, and in silico studies; documented activities include melatonin synthesis modulation, telomerase activity enhancement, interleukin-2 mRNA changes, thymocyte mitogenic activity modulation, AChE/BuChE enhancement, and antioxidant/antimutagenic effects in preclinical and cell-based preparations [Araj et al., 2025; PMID 40141333]

All findings listed above are derived from in silico computational modeling, human stem cell preparations, and a systematic review of preclinical and in vitro studies. Row 1 is a computational binding model. All three rows characterize the unmodified AEDG peptide (Epithalon); no study has studied the N-Acetyl Epithalon Amidate form directly. These observations do not constitute evidence of efficacy or safety for N-Acetyl Epithalon Amidate nasal spray in any organism. No human clinical data has been established for research-grade N-Acetyl Epithalon Amidate administered via the intranasal route.

What are the Potential Research Applications?

In controlled laboratory environments, N-Acetyl Epithalon Amidate nasal spray has been investigated for the following research applications. These are observed in preclinical and in vitro contexts only and do not constitute claims of efficacy or safety in any organism.

Telomerase and Telomere Biology Research

N-Acetyl Epithalon Amidate is investigated as a stabilized reference compound for studying AEDG tetrapeptide effects on telomerase activity and telomere-related gene expression in cell preparations. Research applications include telomerase activity assays in somatic cell preparations, telomere length measurement studies, and investigation of AEDG-telomerase promoter DNA binding interactions in molecular biology model systems.

Epigenetic and Gene Regulation Research

The AEDG tetrapeptide’s histone binding activity and chromatin-level gene regulation effects make N-Acetyl Epithalon Amidate a tool compound for epigenetic research. Research applications include chromatin accessibility studies, neurogenic differentiation gene expression profiling, histone interaction mapping, and comparative epigenetic studies of modified versus unmodified AEDG peptide forms in stem cell and somatic cell preparations.

Neuroendocrine and Pineal Biology Research

The parent compound Epithalon modulates pineal gland function and melatonin synthesis in preclinical preparations. Research applications include melatonin biosynthesis pathway studies, circadian gene expression analysis, neuroendocrine regulation characterization in rodent model systems, and intranasal CNS delivery studies targeting pineal-relevant hypothalamic and cortical structures.

Peptide Stability and End-Capping Research

N-Acetyl Epithalon Amidate provides a direct comparison compound for studying the effects of N-terminal acetylation and C-terminal amidation on tetrapeptide stability and biological activity. Research applications include comparative exopeptidase stability assays between Ac-AEDG-NH2 and Epitalon free acid, and structure-activity relationship studies in peptide bioregulator research programs.

What are the Potential Side Effects?

Researchers in preclinical and in vitro settings have noted the following observations. Long-term safety and toxicity profiles remain incompletely characterized for the research-grade nasal spray formulation.

• Favorable preclinical safety profile of parent compound (preclinical): The parent compound Epithalon has been studied across a broad range of preclinical preparations over 25 years without reports of significant acute toxicity; this class-level observation is relevant to N-Acetyl Epithalon Amidate but does not constitute a formal toxicology assessment for the modified form or the intranasal route
• No confirmed acute toxicity in preclinical models (class context): No acute lethal toxicity has been reported for Epithalon or its analogs at research dose ranges in published preclinical literature; this should not be interpreted as establishing a human safety profile for N-Acetyl Epithalon Amidate nasal spray
• Absence of intranasal-specific safety data: No safety or tolerability data specific to the intranasal route of administration for N-Acetyl Epithalon Amidate has been published in the peer-reviewed literature as of June 2026
• No completed human clinical trials for the modified form: No human Phase 1 safety or efficacy trials for N-Acetyl Epithalon Amidate have been completed or published as of June 2026

No human safety or tolerability data has been established for N-Acetyl Epithalon Amidate nasal spray. These observations are derived from experimental systems and should not be extrapolated to human or animal outcomes.

Risk & Handling

Handling Precautions

Standard laboratory PPE is required: nitrile gloves, a laboratory coat, and eye protection. The following nasal spray-specific precautions apply:

1. Do not direct the nasal spray actuator toward the face, eyes, or mucous membranes during handling, testing, or transfer. CNS-active compounds may produce pharmacological effects via inadvertent intranasal self-exposure.
2. Handle the nasal spray solution in a clean laboratory environment. For aliquoting or analytical sampling, use a laminar flow cabinet.
3. The nasal spray solution is an aqueous formulation susceptible to microbial contamination if compromised. Handle under aseptic conditions. Discard if the solution appears cloudy, discolored, or shows particulate matter.
4. Avoid aerosol generation during any manipulation of the nasal spray solution.

Exposure Risks

Risk Tier: LOW

N-Acetyl Epithalon Amidate is a small tetrapeptide with a 25-year preclinical research history and no reports of significant acute toxicity for the parent compound class. Inadvertent intranasal self-exposure carries a theoretical risk of neuroendocrine modulation given the compound’s pineal and melatonin-related research context. No human safety data exists for the modified form via any route. No human safety or tolerability data has been established for N-Acetyl Epithalon Amidate nasal spray. Researchers should handle this compound with standard precautions appropriate to a biologically active tetrapeptide.

Storage

In-use nasal spray: Store at 2-8°C. Use within 28 days of first actuation. Protect from light. Keep upright.

DO NOT FREEZE the ready-to-use nasal spray formulation. Freezing alters pH, buffer stability, excipient integrity, and spray actuation properties.

Lyophilized bulk stock (if applicable): Store at -20°C in sealed, desiccated, light-protected containers. Avoid repeated freeze-thaw cycles.

Discard any solution that appears cloudy, discolored, or shows visible particulate matter.

FAQs

Q: How does intranasal administration facilitate CNS delivery of N-Acetyl Epithalon Amidate in preclinical research models?

A: Intranasal application allows peptide compounds to access the CNS via the olfactory nerve (cranial nerve I) and trigeminal nerve pathways, bypassing the blood-brain barrier. This transport pathway has been characterized for structurally related peptide compounds in rodent models [Wong et al., 2024; PMID 38441832]. The compound’s small size (~431 Da) facilitates mucosal absorption. N-terminal acetylation and C-terminal amidation reduce exopeptidase susceptibility at the nasal mucosa. No compound-specific olfactory transport data or human delivery data has been established for N-Acetyl Epithalon Amidate nasal spray.

Q: What is the recommended storage and in-use shelf life for N-Acetyl Epithalon Amidate nasal spray?

A: Sealed product should be stored at 2-8°C, protected from light. Once first actuated, in-use shelf life is 28 days at 2-8°C. DO NOT FREEZE the ready-to-use solution. Lyophilized bulk stock should be stored at -20°C in sealed, desiccated, light-protected conditions. Discard if the solution shows cloudiness, discoloration, or particulate matter.

Q: Is the N-Acetyl Epithalon Amidate nasal spray formulation suitable for cell culture or in vitro assay systems?

A: The formulation is prepared in isotonic saline (0.9% NaCl, pH 5.5-6.5) without preservatives. The small size and hydrophilic character of the AEDG tetrapeptide make it generally compatible with aqueous cell culture systems. Dilution into culture medium before application is recommended to normalize pH. Researchers should validate the vehicle independently in their specific cell system and are responsible for confirming compatibility with their assay system.

Q: How does N-Acetyl Epithalon Amidate differ from unmodified Epitalon?

A: Unmodified Epitalon (Ala-Glu-Asp-Gly) is the free acid form with a free N-terminal amino group and C-terminal carboxyl group. N-Acetyl Epithalon Amidate adds N-terminal acetylation and C-terminal amidation. These modifications reduce susceptibility to aminopeptidase and carboxypeptidase degradation and alter the peptide’s charge distribution at physiological pH. The core AEDG sequence and its proposed biological interactions are retained. The pharmacokinetic implications of the modifications have not been formally characterized in published research.

Q: What is the WADA status of N-Acetyl Epithalon Amidate?

A: N-Acetyl Epithalon Amidate is not explicitly named on the 2026 WADA Prohibited List. It is not classified under S2 growth factor categories. As an unapproved pharmacological substance, it may fall under the S0 (Non-Approved Substances) catchall category. Researchers operating within WADA Code contexts should verify current status at GlobalDRO.com prior to any sport-related research application. RCDbio products are supplied for laboratory research purposes only.

Q: What is the FDA regulatory status of N-Acetyl Epithalon Amidate?

A: N-Acetyl Epithalon Amidate is not FDA-approved for any indication. The compound is not among the 19 peptides assigned to the FDA 503A Category 2 bulk drug substance restricted list in 2023. It is not approved for compounding pharmacies for any indication. The research-grade nasal spray supplied by RCDbio is for laboratory research use only and is not a pharmaceutical or compounded product.

Q: What is the evidence base for AEDG peptide research and how should it be interpreted?

A: Epitalon/AEDG peptide research spans 25 years and originates primarily from the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology. A comprehensive 2025 review confirmed significant geroprotective, neuroendocrine, antioxidant, and telomerase-related effects across preclinical and in vitro model systems [Araj et al., 2025; PMID 40141333]. The evidence base is largely concentrated within a small number of research groups, and independent replication is limited. No completed controlled human efficacy trials for Epithalon or N-Acetyl Epithalon Amidate have been published. Researchers should account for this concentrated evidence base when designing and interpreting laboratory protocols.

Related Research Compounds

Researchers investigating N-Acetyl Epithalon Amidate nasal spray may also be interested in the following compounds currently available for laboratory research at RCDbio:

Epitalon Nasal Spray — The unmodified AEDG tetrapeptide free acid form investigated in preclinical preparations for comparative stability, epigenetic gene regulation, and telomerase activity research against the end-capped derivative.

Semax Nasal Spray — A synthetic ACTH(4-7) analog investigated in preclinical rodent preparations for BDNF/TrkB pathway modulation and CNS neurotrophin expression via intranasal delivery; shares peptide bioregulator research heritage with the Khavinson research program.

Selank Nasal Spray — A synthetic analog of the immunomodulatory peptide tuftsin investigated in preclinical preparations for GABA-A receptor modulation and BDNF expression via intranasal delivery.

All products listed are for laboratory and research purposes only.

References

1. Khavinson, V., Shataeva, L., & Chernova, A. (2005). DNA double-helix binds regulatory peptides similarly to transcription factors. Neuro Endocrinology Letters, 26(3), 237-241.

   https://pubmed.ncbi.nlm.nih.gov/15990728/

2. Khavinson, V., Diomede, F., Mironova, E., Linkova, N., Trofimova, S., Trubiani, O., Caputi, S., & Sinjari, B. (2020). AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Molecules, 25(3), 609.

   https://pubmed.ncbi.nlm.nih.gov/32019204/

3. Araj, S.K., Brzezik, J., Madra-Gackowska, K., & Szeleszczuk, L. (2025). Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences, 26(6), 2691.

   https://pubmed.ncbi.nlm.nih.gov/40141333/

4. Wong, C.Y.J., Baldelli, A., Hoyos, C.M., et al. (2024). Insulin delivery to the brain via the nasal route: unraveling the potential for Alzheimer’s Disease therapy. Drug Delivery and Translational Research, 14(7), 1776-1793.

   https://pubmed.ncbi.nlm.nih.gov/38441832/

Research Transparency Note: No peer-reviewed publications specific to intranasal delivery of N-Acetyl Epithalon Amidate are available as of June 2026. References 1-3 above characterize the unmodified Epitalon (AEDG) tetrapeptide in computational models, human stem cell preparations, and a systematic review; no study has examined the N-acetyl/amidated derivative directly. These are cited as a mechanistic and pharmacological context for the AEDG tetrapeptide core sequence retained in N-Acetyl Epithalon Amidate. The olfactory transport pathway evidence in Reference 4 is class-level and applies to structurally related peptide compounds in rodent models. The majority of primary Epitalon research originates from the Khavinson research group at the St. Petersburg Institute of Bioregulation and Gerontology; independent replication of the full range of reported effects is limited.

Disclaimer

N-Acetyl Epithalon Amidate Nasal Spray is exclusively for laboratory research purposes. RCDbio products are not intended to diagnose, prevent, treat, or cure any disease or medical condition.

The Food and Drug Administration has not evaluated the statements on our website. This product is not approved for human or veterinary use. Researchers must comply with all applicable local, state, and federal laws and regulations governing the purchase and use of research compounds. By purchasing, you agree to our Terms and Conditions. RCDbio reserves the right to refuse sales to unauthorized individuals.

ATTENTION: All RCDbio products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not intended for human consumption, veterinary use, or any other non-research application. For queries, complaints, or support, contact support@legacy.rcdbio.co